[go: up one dir, main page]

AU2002212894A1 - N-type calcium channel antagonists for the treatment of pain - Google Patents

N-type calcium channel antagonists for the treatment of pain

Info

Publication number
AU2002212894A1
AU2002212894A1 AU2002212894A AU1289402A AU2002212894A1 AU 2002212894 A1 AU2002212894 A1 AU 2002212894A1 AU 2002212894 A AU2002212894 A AU 2002212894A AU 1289402 A AU1289402 A AU 1289402A AU 2002212894 A1 AU2002212894 A1 AU 2002212894A1
Authority
AU
Australia
Prior art keywords
treatment
pain
calcium channel
type calcium
channel antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002212894A
Inventor
Marc Chapdelaine
Bipinchandra Chaudhari
Greg Hostetler
Lucius Kemp
John Mccauley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2002212894A1 publication Critical patent/AU2002212894A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds useful for the treatment of pain in accord with the following structural diagram, wherein R<1>, R<2 >and R<3 >are any of a number of groups as defined in the specification and pharmaceutical compositions and methods of treatment utilising such compounds.
AU2002212894A 2000-11-06 2001-10-31 N-type calcium channel antagonists for the treatment of pain Abandoned AU2002212894A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0004053A SE0004053D0 (en) 2000-11-06 2000-11-06 N-type calcium channel antagonists for the treatment of pain
SE0004053 2000-11-06
PCT/SE2001/002388 WO2002036586A1 (en) 2000-11-06 2001-10-31 N-type calcium channel antagonists for the treatment of pain

Publications (1)

Publication Number Publication Date
AU2002212894A1 true AU2002212894A1 (en) 2002-05-15

Family

ID=20281713

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002212894A Abandoned AU2002212894A1 (en) 2000-11-06 2001-10-31 N-type calcium channel antagonists for the treatment of pain

Country Status (9)

Country Link
US (1) US6815447B2 (en)
EP (1) EP1339706B1 (en)
JP (1) JP2004513125A (en)
AT (1) ATE323693T1 (en)
AU (1) AU2002212894A1 (en)
DE (1) DE60118956T2 (en)
ES (1) ES2261496T3 (en)
SE (1) SE0004053D0 (en)
WO (1) WO2002036586A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259866A1 (en) * 1998-06-30 2004-12-23 Snutch Terrance P. Calcium channel blockers comprising two benzhydril moieties
MXPA04011472A (en) * 2002-05-22 2005-02-14 Amgen Inc Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain.
WO2004014871A1 (en) 2002-08-08 2004-02-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
MXPA05005477A (en) 2002-11-21 2005-07-25 Chiron Corp 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer.
WO2005051392A1 (en) * 2003-11-20 2005-06-09 Children's Hospital Medical Center Gtpase inhibitors and methods of use
WO2006089311A1 (en) 2005-02-15 2006-08-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CA2603926A1 (en) * 2005-04-08 2006-10-12 Neuromed Pharmaceuticals Ltd. Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
CA2651811A1 (en) * 2006-05-11 2007-11-22 Neuromed Pharmaceuticals Ltd. Method for increasing the bioavailability of benzhydryl piperazine containing compounds
CA2675558A1 (en) 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
WO2011109254A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
US9309199B2 (en) 2010-03-04 2016-04-12 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
WO2011109267A1 (en) * 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
AU2012225459A1 (en) 2011-03-08 2013-10-10 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
WO2013046136A1 (en) 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UY34632A (en) 2012-02-24 2013-05-31 Novartis Ag OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
EA028033B1 (en) 2013-03-14 2017-09-29 Новартис Аг 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB794043A (en) 1955-06-03 1958-04-30 Ici Ltd New quinoline derivatives
CA2325638A1 (en) * 1998-03-26 1999-09-30 Hideki Yamada Amide derivatives and nociceptin antagonists

Also Published As

Publication number Publication date
DE60118956D1 (en) 2006-05-24
SE0004053D0 (en) 2000-11-06
ATE323693T1 (en) 2006-05-15
US20040058945A1 (en) 2004-03-25
JP2004513125A (en) 2004-04-30
EP1339706A1 (en) 2003-09-03
WO2002036586A1 (en) 2002-05-10
EP1339706B1 (en) 2006-04-19
ES2261496T3 (en) 2006-11-16
DE60118956T2 (en) 2007-03-15
US6815447B2 (en) 2004-11-09

Similar Documents

Publication Publication Date Title
AU2002212894A1 (en) N-type calcium channel antagonists for the treatment of pain
MY115662A (en) Novel compounds with analgesic effect
PL366198A1 (en) Novel compounds
GB0128996D0 (en) Organic compounds
MY119403A (en) Novel compounds with analgesic effect.
ZA9710796B (en) Oxyiminopregnanecarbolactones.
SE0102858D0 (en) N-type calcium channel antagonists for the treatment of pain
PL1654253T3 (en) Substituted 3-pyrrolidin-indole derivatives
MY133969A (en) Indoloquinazolinones
SE9802208D0 (en) Novel compounds
SE0004054D0 (en) N-type calcium channel antagonists for the treatment of pain
BG104916A (en) Calcilytic compounds
YU13301A (en) Muscarinic agonists and antagonists
AU1843397A (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
SE0203070D0 (en) Novel compounds
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
AU2002368133A1 (en) 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
AU2420001A (en) Methods and compositions for the treatment of pain
NZ515108A (en) Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments
SE9802209D0 (en) Novel compounds
BR9713176A (en) Amorphous benzothiophenes, methods of preparation and methods of use
AU2002212897A1 (en) N-type calcium channel antagonists for the treatment of pain
SE9504662D0 (en) New compounds
AU4925200A (en) Oral composition containing perlite
AU2566101A (en) Compounds and methods for the treatment of pain